Dimerix Ltd has released a press release.
Key Patent Allowed in Japan
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Dimerix Raises $2 million to Advance Clinical Program
- Recruitment of Part A of Phase 2 Trial of DMX-200 Completed
- Appointment of Chief Executive Officer
- Update presentation - interim data
- Positive interim analysis of DMX-200 phase II data
Later from Dimerix
- Corporate Presentation
- Receipt of $420k Research & Development Tax Refund
- Investor Update
- Research Validates Relevance of DMX Receptor-HIT Technology
- Positive Results from Phase 2a Trial of DMX-200
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix